In terms of research and diagnostics, the most important news that emerged during the recent ICML conference is the role that "liquid biopsy" plays in the detection of tumor specific DNA in the patient's peripheral blood. The early diagnosis of the reappearance of the tumor when there are still no symptoms and the disease is not yet aggressive allows us to adopt the most effective treatment well in advance.
In terms of research and diagnostics, the most important news that emerged during the recent ICML conference is the role that "liquid biopsy" plays in the detection of tumor specific DNA in the patient's peripheral blood. The early diagnosis of the reappearance of the tumor when there are still no symptoms and the disease is not yet aggressive allows us to adopt the most effective treatment well in advance.
ICML 2019 - Lugano
Moving forward in chronic lymphocytic leukemia treatment
The efficacy of Liquid Biopsy in the detection of blood tumor DNA
L'efficacia della Biopsia Liquida per seguire il decorso dei linfomi
Moving forward in aggressive lymphoma
State of the art of treatments in chronic lymphocytic leukemia
Lenalidomide/R‐CHOP fase II study results
Gene therapy for lymphomas and Liquid Biopsy
Questions & Answers: the difference between CAR-T and bio-specific cells
Efficacy and fields of application of the CAR-T cell therapy
Questions & Answers: the CAR-T cell therapy situation in Switzerland
B-cell lymphoma: the efficacy and safety of ADCT-402
Questions & Answers: Chronic lymphocytic leukemia, treatment of asymptomatic patient
Large B-cell lymphoma: two studies compared
B-cell Non-Hodgkin's Lymphoma: treatment with new antibodies
